Lyndra Therapeutics achieved significant milestones in the first half of 2020 despite COVID-19 headwinds, naming Örn Almarsson as Chief Technology Officer, completing enrollment and dosing of its Phase I clinical trial for an ultra-long-acting oral risperidone therapy to treat schizophrenia, ramping up manufacturing capabilities and growing its employee base by 28%.
June 11, 2020
· 5 min read